Neuphoria Therapeutics (NEUP) Other Operating Expenses (2025 - 2026)
Neuphoria Therapeutics (NEUP) reported Other Operating Expenses of -$475754.0 for Q1 2026, down 138.49% on a QoQ basis from $1.2 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 2 years of Other Operating Expenses data on file, last reported at -$475754.0 in Q1 2026.
- Quarterly Other Operating Expenses changed N/A year-over-year to -$475754.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $760418.0 (changed N/A YoY) and the FY2020 annual result came in at -$1.1 million, changed N/A from the prior year.
- Other Operating Expenses declined to -$475754.0 in Q1 2026 per NEUP's latest filing, from $1.2 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $1.2 million in Q4 2025 and bottomed at -$475754.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -475,754.00 |
| Dec 31, 2025 | 1.24 Mn |